Roche Strikes USD 2.3 Billion Nurix Deal for Blood Cancer Drug Bexobrutideg
Zurich: Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to USD 2.3 billion, the company said on Monday.
The deal focuses on blood cancer drug bexobrutideg, which degrades targeted proteins and is planned to enter a phase III clinical trial initiation for chronic lymphocytic leukaemia (CLL) in the summer.
Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.
"We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases," Levi Garraway, Roche chief medical officer and head of global product development said
The deal is expected to close in the third quarter of 2026
Development costs for the drug will be covered 60% by Roche and 40% by Nurix
The companies will co-commercialise the drug in the United States, where they will split the profits and losses equally, while Roche will commercialise outside of the U.S., paying Nurix royalties
